Optimizing Care for Challenging People Living With HIV

March 18, 2024 updated by: Chun-Yuan Lee, MD, Kaohsiung Medical University Chung-Ho Memorial Hospital

Feasible Program of Sustainable Medical Care for People Living With HIV Who Are Difficult to Treat or Marginalized in Taiwan

Conduct an intervention combining social and behavioral health models with digital health technologies to improve their adherence to their medication schedules. The success of the intervention is assessed by comparing adherence rates before and after its implementation to see if there's a notable enhancement in how well patients follow their antiretroviral therapy.

Study Overview

Status

Enrolling by invitation

Detailed Description

This is an intervention strategy for HIV-infected individuals based on their viral load measurements and medication adherence rates, measured by the proportion of days covered (PDC) for the past 365 days. A specific PDC threshold identifies individuals with less than 90% viral suppression at under 200 copies/mL. An intervention approach integrating social and behavioral models with electronic health (eHealth) technology is implemented for cases with a PDC below this threshold. The intervention aims to enhance the patient's adherence to their medication regimen. The effectiveness of this intervention is evaluated by comparing indicators before and after its application to determine if there are significant improvements in the participants' compliance with their antiretroviral therapy.

Study Type

Interventional

Enrollment (Estimated)

210

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Kaohsiung city, Taiwan, 814032
        • Kaohsiung Medical University Chung-Ho Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

1. PLWH with adherence below the specific proportion of days covered (PDC), which is defined as the specific level that corresponds to 90% at viral suppression (< 200 copies/mL).

Exclusion Criteria:

  1. Under 18 years of age.
  2. Illiterate.
  3. Non-consenting individuals.
  4. Less than 365 days from the initial use of antiretroviral drugs to the assessment for inclusion in the study.
  5. Inability to obtain complete medication records for the 365 days prior to inclusion.
  6. Lack of a smart phone.
  7. No willingness to return for follow-up at the participating hospital.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: People living with HIV with poor adherence to HAART
People living with HIV (PLWH) with adherence below the specific proportion of days covered (PDC), which is defined as the specific level that corresponds to 90% at viral suppression (< 200 copies/mL).

The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q&A services.

The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.

The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparative Analysis of Baseline Versus 1st and 2nd Follow-Up Assessments on Viral Load in copies/mL
Time Frame: At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Compare the data on Viral Load in copies/mL between Baseline Versus 1st and 2nd Follow-Up
At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Comparative Analysis of Baseline Versus 1st and 2nd Follow-Up Assessments on CD4 Count in cells/mm^3
Time Frame: At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Compare the data on cluster of differentiation 4 (CD4) Count in cells/mm^3 between Baseline Versus 1st and 2nd Follow-Up
At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Comparative Analysis of Baseline Versus 1st and 2nd Follow-Up Assessments on WHOQOL-BREF Taiwan Version in score
Time Frame: At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Compare the data on WHOQOL-BREF Taiwan Version in score between Baseline Versus 1st and 2nd Follow-Up
At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Comparative Analysis of Baseline Versus 1st and 2nd Follow-Up Assessments on HIV symptoms index (HIV-SI) in score
Time Frame: At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Compare the data on HIV symptoms index (HIV-SI) in score between Baseline Versus 1st and 2nd Follow-Up
At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Comparative Analysis of Baseline Versus 1st and 2nd Follow-Up Assessments on Self-Reported Medication Adherence in percentage
Time Frame: At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment
Compare the data on Self-Reported Medication Adherence in percentage between Baseline Versus 1st and 2nd Follow-Up
At baseline, 84th (+-14) day after enrollment, and 168th (+-14) day after enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in Proportion of Days Covered (PDC) at the Second Follow-Up Compared to Baseline over the Past 180 Days
Time Frame: At baseline and 168th (+-14) day after enrollment
To compare the data on PDC over the past 180 days between Baseline Versus 2nd Follow-Up
At baseline and 168th (+-14) day after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Chun-Yuan Lee, M.D., Kaohsiung Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 18, 2024

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

December 6, 2023

First Submitted That Met QC Criteria

December 14, 2023

First Posted (Actual)

December 27, 2023

Study Record Updates

Last Update Posted (Actual)

March 20, 2024

Last Update Submitted That Met QC Criteria

March 18, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on Combination of social-behavior model and eHealth

3
Subscribe